TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection
Brief Summary: The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective in preventing sternal wound infections in patients undergoing cardiac surgery who are at a greater risk of developing sternal wound infections.


Options:
A: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
D: Arm Label: gentamicin Group; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge dipped in saline | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: gentamicin-collagen sponge dipped in saline; Assigned to Arm(s): gentamicin Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control
Brief Summary: The hypothesis of this trial is that the therapeutic activity and safety of oral miltefosine in Brazilian patients with cutaneous leishmaniasis is similar or superior to the intravenous standard treatment (meglumine antimoniate - Glucantime®).


Options:
A: Arm Label: Intralesional antimony; Type: EXPERIMENTAL; Interventions: Drug: pentavalent antimony | Arm Label: Cryotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: cryotherapy | Arm Label: Topical cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo cream | Intervention Type: DRUG; Name: pentavalent antimony; Assigned to Arm(s): Intralesional antimony | Intervention Type: PROCEDURE; Name: cryotherapy; Assigned to Arm(s): Cryotherapy | Intervention Type: DRUG; Name: placebo cream; Assigned to Arm(s): Topical cream
B: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
C: Arm Label: 1.1; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine. | Arm Label: 1.2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate. | Arm Label: 2.1; Type: EXPERIMENTAL; Interventions: Drug: Miltefosine. | Arm Label: 2.2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate. | Intervention Type: DRUG; Name: Miltefosine.; Assigned to Arm(s): 1.1 | Intervention Type: DRUG; Name: Meglumine antimoniate.; Assigned to Arm(s): 1.2 | Intervention Type: DRUG; Name: Miltefosine.; Assigned to Arm(s): 2.1 | Intervention Type: DRUG; Name: Meglumine antimoniate.; Assigned to Arm(s): 2.2
D: Intervention Type: BIOLOGICAL; Name: Leish-111f + MPL-SE vaccine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Biobehavioral Effects of Mindfulness-Based Stress Reduction in HIV
Brief Summary: The purpose of this study is to investigate whether Mindfulness-Based Stress Reduction (MBSR) vs a one-day MBSR seminar improves immune (CD4+ T lymphocytes) and virological (HIV viral load) status in HIV-1 infected adults. The secondary goal of the study is to determine if MBSR vs a one-day MBSR seminar improves self-reported HIV-related quality of life.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone-administered supportive-expressive therapy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone-administered coping improvement therapy | Intervention Type: BEHAVIORAL; Name: Telephone-administered coping improvement therapy; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Telephone-administered supportive-expressive therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Individual therapy; Assigned to Arm(s): 1
B: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU
C: Arm Label: 1-Day MBSR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MBSR | Arm Label: 8-week MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR | Intervention Type: BEHAVIORAL; Name: MBSR; Assigned to Arm(s): 1-Day MBSR, 8-week MBSR
D: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
Brief Summary: The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment.

The objective of this study was to compare the proportion of patients with a reduction of mean GH level to \<2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months.

Following one year of treatment patients could proceed into the study extension.

Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) were switched to the other treatment arm at month 13.


Options:
A: Arm Label: octreotide; Type: EXPERIMENTAL; Interventions: Drug: Octreotide | Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Direct surgery for acromegaly | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): octreotide | Intervention Type: PROCEDURE; Name: Direct surgery for acromegaly; Assigned to Arm(s): standard surgery
B: Arm Label: Pasireotide LAR 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Pasireotide LAR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Control arm (octreotide or lanreotide); Type: ACTIVE_COMPARATOR; Interventions: Drug: octreotide LAR 30mg, Drug: lanreotide ATG 120mg | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR 40 mg, Pasireotide LAR 60 mg | Intervention Type: DRUG; Name: octreotide LAR 30mg; Assigned to Arm(s): Control arm (octreotide or lanreotide) | Intervention Type: DRUG; Name: lanreotide ATG 120mg; Assigned to Arm(s): Control arm (octreotide or lanreotide)
C: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide LAR | Intervention Type: DRUG; Name: Pasireotide LAR; Assigned to Arm(s): Pasireotide LAR
D: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide LAR

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Brief Summary: The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective for preventing surgical wound infections in patients undergoing colorectal surgery.


Options:
A: Intervention Type: DRUG; Name: Cefmetazole (drug); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge dipped in saline | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: gentamicin-collagen sponge dipped in saline; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: Intra-peritoneal antibiotic lavage; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: MK0826, ertapenem sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: cefotetan; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions
Brief Summary: This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions.

The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a medicine called deferasirox (ICL670) with another medicine called deferoxamine (DFO). The study is aimed at finding out which of the two medicines is the best for treating iron overload in the heart.

Patients will be treated for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study treatment in a 12 months extension phase. During the core and extension, the effects of treatment on iron overload in the heart and the liver will be evaluated using specific magnetic resonance imaging (MRI) assessments.


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
B: Arm Label: Deferiprone; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): Deferiprone | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferoxamine
C: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
D: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions
Brief Summary: This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions.

The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a medicine called deferasirox (ICL670) with another medicine called deferoxamine (DFO). The study is aimed at finding out which of the two medicines is the best for treating iron overload in the heart.

Patients will be treated for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study treatment in a 12 months extension phase. During the core and extension, the effects of treatment on iron overload in the heart and the liver will be evaluated using specific magnetic resonance imaging (MRI) assessments.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
B: Arm Label: ICL670 (Deferasirox); Type: EXPERIMENTAL; Interventions: Drug: Deferasirox | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): ICL670 (Deferasirox)
C: Arm Label: Thalassemia cohort; Type: N/A; Interventions: N/A | Arm Label: Successful SCT cohort; Type: N/A; Interventions: N/A
D: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
Brief Summary: Hemangiomas of infancy, the most common benign tumors of infancy, are congenital or early infancy lesions characterized by a rapid postnatal growth, with high expression of angiogenic stimulators for 9-18 months, followed by slow regression for 5-9 years. Current therapies for the hemangiomas are usually restricted to more severe forms due to the risks of adverse effects, inconvenience and cost. Nevertheless, a substantial amount of the psychological discomfort and morbidity can be caused by untreated hemangiomas, especially those in the face.

Recently, Imiquimod 5% cream has emerged as a safe an effective drug for several skin conditions that benefit from modulation of the activity of the immune system, such as common warts and various forms of the skin pre-cancerous and cancerous lesions. Small case reports series have suggest that it could also be useful in hemangiomas, possibly through the inhibition of the angiogenesis by local IFN production.This is a small, open label study of 16 patients to document the efficacy of the Imiquimod 5% cream in the treatment of hemangioma of infancy (primary outcome). IFN and plasma drug levels, as well as clinical examinations and blood studies, will be carried out to evaluate safety of the treatment (secondary outcome). bFGF and VEGF will be measured in blood and urine in order to study the diagnostic and predictive value of these pro-angiogenic factors in the response of hemangiomas to the treatment with Imiquimod (secondary outcome).

The study is a phase II clinical trial of a once a day application of Imiquimod 5% cream, 3 to 7 times per week for a maximum of four months. The study held at the Dermatology Clinic of Sainte-Justine Hospital, and was completed within a 20 months timeframe after IRB approval.


Options:
A: Arm Label: Cryocontact therapy; Type: EXPERIMENTAL; Interventions: Procedure: cryocontact therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Procedure: cryocontact therapy, Other: Control | Intervention Type: PROCEDURE; Name: cryocontact therapy; Assigned to Arm(s): Control, Cryocontact therapy | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: propranolol for treatment of hemangiomas; Type: EXPERIMENTAL; Interventions: Drug: propranolol | Arm Label: Prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: propranolol; Assigned to Arm(s): propranolol for treatment of hemangiomas | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Prednisolone
C: Arm Label: Propranolol oral solution; Type: EXPERIMENTAL; Interventions: Drug: Propranolol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol oral solution | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Imiquimod 5% cream; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Phase IV Trial to Assess the Efficacy of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Reduce or Replace Cigarette Smoking Among Adult Smokers in Serbia
Brief Summary: The study aims to establish if a low-nitrosamine, smokeless tobacco product (Swedish snus) can help adult smokers to reduce and eventually completely quit smoking.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Swedish snus (smokeless tobacco) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Onico | Intervention Type: OTHER; Name: Swedish snus (smokeless tobacco); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Onico; Assigned to Arm(s): 2
B: Arm Label: CO reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Informing surgical patients about CO monitoring | Arm Label: no CO reminder; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: a brief intervention recommending preoperative abstinence from smoking | Intervention Type: BEHAVIORAL; Name: Informing surgical patients about CO monitoring; Assigned to Arm(s): CO reminder | Intervention Type: BEHAVIORAL; Name: a brief intervention recommending preoperative abstinence from smoking; Assigned to Arm(s): no CO reminder
C: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Phase IV Trial to Assess the Efficacy of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Reduce or Replace Cigarette Smoking Among Adult Smokers in Serbia
Brief Summary: The study aims to establish if a low-nitrosamine, smokeless tobacco product (Swedish snus) can help adult smokers to reduce and eventually completely quit smoking.


Options:
A: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
B: Arm Label: Less Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: More Dependent Smokers; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Less Dependent Smokers, More Dependent Smokers
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Swedish snus (smokeless tobacco) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Onico | Intervention Type: OTHER; Name: Swedish snus (smokeless tobacco); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Onico; Assigned to Arm(s): 2
D: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C